{"name":"BIOXYDYN LIMITED","company_number":"06838431","status":"Active","type":"Private Limited Company","incorporated":"2009-03-05","dissolved":null,"registered_office":"St James Tower, 7 Charlotte Street, Manchester, England, M1 4DZ","postcode":"M1 4DZ","sic_codes":[{"code":72110,"description":"Research and experimental development on biotechnology"}],"principal_activity":null,"previous_names":[],"warnings":[],"accounts":{"category":"Total Exemption Full","year_end":"30 November","last_made_up_to":"2025-11-30","next_due":"2027-08-31"},"employees":{"count":7,"accounts_date":"2025-11-30"},"financials":[{"financial_date":"2025-11-30","net_assets":740011,"cash":17949,"average_employees":7},{"financial_date":"2024-11-30","net_assets":724307,"cash":21966,"average_employees":7},{"financial_date":"2023-11-30","net_assets":707207,"cash":47967,"average_employees":8},{"financial_date":"2022-11-30","net_assets":593661,"cash":7301},{"financial_date":"2021-11-30","net_assets":604472,"cash":185617}],"officers":{"current":5,"resigned":8,"complete":true,"note":"Names and details of individual officers are on the People page (subscriber-only on this site) and free at Companies House."},"charges":{"total":0,"outstanding":0},"gazette_notices":[],"insolvency_outcome":null,"ai_summary":"BIOXYDYN LIMITED possesses valuable biotechnology IP and credible institutional backing, but its strategic position is fundamentally threatened by acute liquidity constraints and a 15-year track record of accumulated losses totalling £2.5 million. The 113% growth in trade debtors signals emerging commercial traction, yet with only £17,949 in cash and negative working capital, the company faces an existential funding gap within months rather than years. The immediate strategic imperative is securing bridge financing—whether through investor loans, grant funding, or licensing partnerships—while accelerating the conversion of capitalised R&D into revenue-generating commercial agreements, before the patience of institutional backers and the viability of the enterprise converge toward an unfavourable resolution.","website":"http://bioxydyn.com","links":{"page":"https://www.companiesintheuk.co.uk/ltd/bioxydyn","people":"https://www.companiesintheuk.co.uk/company/bioxydyn/people","filing_history":"https://www.companiesintheuk.co.uk/company/bioxydyn/filing-history","companies_house":"https://find-and-update.company-information.service.gov.uk/company/06838431","financials":"https://www.companiesintheuk.co.uk/company/bioxydyn/financial","control":"https://www.companiesintheuk.co.uk/company/bioxydyn/control","charges":"https://www.companiesintheuk.co.uk/company/bioxydyn/charges","ai_analysis":"https://www.companiesintheuk.co.uk/company/bioxydyn/analysis"},"source":"CompaniesInTheUK, from Companies House, The Gazette and other public registers (see /support/about). Cite as: CompaniesInTheUK, https://www.companiesintheuk.co.uk/ltd/bioxydyn"}